MCL1 and non-Hodgkin lymphoma: Although our data are broadly in line with recently published clinical trial data for venetoclax in NHL [8], we found a potential impact for MCL-1 dependency after CHOP treatment, which might indicate that a significant number of patients would derive greater benefit from a MCL-1 inhibitor than from venetoclax treatment.